Correction to: Nature Communications https://doi.org/10.1038/ncomms10787, published online 23 February 2016
The original version of this Article contained the following errors:
The original version of this Article contained an error in the legend of Fig. 5c, which incorrectly omitted the following: ‘Please note that the same control was published in a previous article65 that reported the results obtained for other inhibitors of L55P-TTR aggregation that were tested in the same dot blot assay.’ This error has been corrected in both the PDF and HTML versions of the Article.
The original version of this Article omitted a reference to previous work in ‘Ferreira, N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics 11, 450–461 (2014)’. This has been added as reference 65 in the legend of Fig. 5c, as described above. This error has been corrected in both the PDF and HTML versions of the Article.
In addition, the original version of the Supplementary Information associated with this Article contained errors in Supplementary Fig. 8, which showed an incomplete dot blot and was accompanied by an incomplete legend, which incorrectly read ‘Selected images of the dot blot used in main figure 5c.’ The correct version of the legend states ‘Uncropped blot for results shown in Figure 5c. Several compounds (including tolcapone, tafamidis, EGCG and CLR01) were tested in the same dot blot assay as potential inhibitors of L55P-TTR aggregation, sharing the same controls (no inhibitor) on an acetate cellulose membrane. Figure 5c showed the results obtained for the control, tolcapone and tafamidis, while a previous article showed the results obtained for the control, CLR01 and EGCG: Ferreira, N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics 11, 450–461 (2014).’ The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version of Supplementary Fig. 8 can be found as Supplementary Information associated with this Correction.
Author information
Authors and Affiliations
Corresponding authors
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sant’Anna, R., Gallego, P., Robinson, L.Z. et al. Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun 14, 582 (2023). https://doi.org/10.1038/s41467-023-36239-z
Published:
DOI: https://doi.org/10.1038/s41467-023-36239-z
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
